STELLAR-305：zan zalintinib联合帕博利珠单抗对比单独使用帕博利珠单抗治疗头颈部鳞状细胞癌患者的II/III期研究。
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.
作者信息
Saba Nabil F, Harrington Kevin, Licitra Lisa, Machiels Jean-Pascal, He Cixin, Jew Taylor, Andrianov Vasily, Haddad Robert
机构信息
Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, USA.
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
出版信息
Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18.
Abstract
TWEETABLE ABSTRACT
STELLAR-305: design of an ongoing phase III #clinicaltrial, assessing the multi-targeted tyrosine kinase inhibitor, zanzalintinib, in combination with pembrolizumab in previously untreated recurrent/metastatic #HNSCC.
CLINICAL TRIAL REGISTRATION
NCT06082167 (ClinicalTrials.gov).
摘要
可发布推文的摘要
STELLAR - 305：一项正在进行的III期#临床试验设计，评估多靶点酪氨酸激酶抑制剂赞扎替尼与帕博利珠单抗联合用于既往未治疗的复发/转移性#头颈部鳞状细胞癌。
临床试验注册
NCT06082167（ClinicalTrials.gov）。
相似文献
1
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.
Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18.
2
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.
Future Oncol. 2025 Jul;21(16):2007-2016. doi: 10.1080/14796694.2025.2511470. Epub 2025 Jun 13.
3
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23.
4
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
6
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Safety and efficacy of neoadjuvant therapy with tislelizumab plus chemotherapy for locally advanced head and neck squamous cell carcinoma: a single-arm, retrospective study.
Cancer Immunol Immunother. 2025 Feb 11;74(3):108. doi: 10.1007/s00262-025-03953-0.
本文引用的文献
1
Advances in understanding cisplatin-induced toxicity: Molecular mechanisms and protective strategies.
Eur J Pharm Sci. 2024 Dec 1;203:106939. doi: 10.1016/j.ejps.2024.106939. Epub 2024 Oct 17.
2
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202.
3
Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
Oral Oncol. 2024 Nov;158:106997. doi: 10.1016/j.oraloncology.2024.106997. Epub 2024 Aug 17.
4
STELLAR-303: randomized phase III study of zanzalintinib + atezolizumab in previously treated metastatic colorectal cancer.
Future Oncol. 2024;20(24):1733-1743. doi: 10.1080/14796694.2024.2352276. Epub 2024 Jul 23.
5
MET Oncogene Targeting for Cancer Immunotherapy.
Int J Mol Sci. 2024 Jun 1;25(11):6109. doi: 10.3390/ijms25116109.
6
The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
Oral Oncol. 2024 Jun;153:106799. doi: 10.1016/j.oraloncology.2024.106799. Epub 2024 May 9.
7
Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433330. doi: 10.1200/EDBK_433330.
8
Therapeutic targeting of the functionally elusive TAM receptor family.
Nat Rev Drug Discov. 2024 Mar;23(3):201-217. doi: 10.1038/s41573-023-00846-8. Epub 2023 Dec 13.
9
TAM family kinases as therapeutic targets at the interface of cancer and immunity.
Nat Rev Clin Oncol. 2023 Nov;20(11):755-779. doi: 10.1038/s41571-023-00813-7. Epub 2023 Sep 4.
10
Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Nat Med. 2023 Apr;29(4):880-887. doi: 10.1038/s41591-023-02275-x. Epub 2023 Apr 3.
Zotero 插件